Saturday, November 21, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&ADaewoong Q3 profit up 43.5% on Nabota exports2 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekBusiness & M&AEvolus eyes Sculpt filler launch in Q1 20274 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AInMode Q3 revenue holds near $92.1M, margins sliplast weekBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryMexico approves Restylane Shaype for jawline firstlast weekRegulatoryFDA clears Shenzhen Bway red/NIR LED face masklast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boostlast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patchlast weekDevices & TechConexeu's first human collagen batch meets its own specslast weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin saleslast week
Regulatory

Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know

The FDA issued a Complete Response Letter for RelabotulinumtoxinA, delaying Galderma's entry into the U.S. neuromodulator market.

Scientist analyzing samples in a lab with various test tubes and equipment.
Photo: Polina Tankilevitch / Pexels
1-YEAR MOVE
+15% −13%
ABBV ▲11.6%
1-year price move by ticker
TickerCompany1-year change
ABBVAbbVie (Allergan Aesthetics)+11.6%

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Galderma received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA (Relfydess), its proposed competitor to Botox and Dysport. The CRL signals the agency will not approve the application in its current form, requiring additional data or manufacturing clarification before resubmission.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

The CRL marks the second FDA setback for Galderma's neuromodulator entry, extending the timeline for a third botulinum toxin option in the U.S.

This is Galderma's second regulatory setback for the product. The delay extends the timeline for a third botulinum toxin option in the U.S. market—a space currently dominated by AbbVie's Botox and Revance's Dysport. For practices, the competitive pressure that might have driven pricing or rebate concessions from incumbents is now pushed further out. Galderma's stock fell sharply on the news, reflecting investor disappointment in the company's ability to diversify its injectables portfolio beyond Restylane fillers.

Source: original report ↗

Frequently asked questions

What is a Complete Response Letter from the FDA?

A Complete Response Letter (CRL) means the FDA will not approve a drug application in its current form and requires the manufacturer to submit additional data, clinical evidence, or manufacturing information before resubmission. It's a formal rejection that delays market entry but allows the company to address specific deficiencies and reapply.

When will Relfydess be available in the US?

Relfydess does not have an approved timeline for U.S. market entry. Galderma received a Complete Response Letter, meaning the product must undergo additional FDA review and resubmission before approval is possible. The delay extends beyond the original expected timeline.

How many botulinum toxin brands are available in the US?

Currently, two botulinum toxin brands dominate the U.S. market: AbbVie's Botox and Revance's Dysport. Relfydess would have been the third option, but its FDA approval is now delayed due to the Complete Response Letter.

Will Relfydess approval affect Botox and Dysport pricing?

The FDA delay for Relfydess removes near-term competitive pressure that could have driven price concessions or rebates from Botox and Dysport manufacturers. Practices should not expect pricing changes from incumbents in the near future as a result of this setback.

Is this Galderma's first FDA rejection for Relfydess?

No, this is Galderma's second regulatory setback for RelabotulinumtoxinA. The company has previously encountered FDA obstacles, indicating ongoing challenges in meeting the agency's approval requirements for this product.

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/galderma-relabotulinumtoxina-fda-complete-response-letter/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →